| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
AJP - Endocrinology and Metabolism, Vol 271, Issue 4 E742-E747, Copyright © 1996 by American Physiological Society
ARTICLES |
S. Sreenan, J. Sturis, W. Pugh, C. F. Burant and K. S. Polonsky
Department of Medicine, University of Chicago, Illinois 60637, USA.
To determine whether metformin or troglitazone can delay the onset of diabetes in the Zucker diabetic fatty (ZDF) rat, lean control, fatty, and ZDF rats received metformin, troglitazone, or no treatment from 6 to 12 wk of age. Glucose, insulin, triglyceride (TG), and free fatty acid (FFA) levels and glucose stimulated insulin secretion by the perfused pancreas were measured. Metformin-treated rats gained significantly less weight. Both drugs prevented hyperglycemia by 12 wk in diabetic rats and significantly reduced TG and FFA levels. Insulin secretion at low glucose was elevated in untreated fatty and diabetic animals, and the increment in diabetic animals produced by glucose perfusion was attenuated compared with lean and fatty rats. Both drugs reduced basal insulin secretion in fatty and diabetic rats and improved glucose responsiveness in diabetic rats. Metformin and troglitazone delay the onset of diabetes in the ZDF rat. The significantly improved insulin secretory response of the pancreas undoubtedly contributes to the improved glucose tolerance.
This article has been cited by other articles:
|
|
 |
|
  A. C. Smith, K. L. Mullen, K. A. Junkin, J. Nickerson, A. Chabowski, A. Bonen, and D. J. Dyck Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E172 - E181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Leclerc, W. W. Woltersdorf, G. da Silva Xavier, R. L. Rowe, S. E. Cross, G. S. Korbutt, R. V. Rajotte, R. Smith, and G. A. Rutter Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1023 - E1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Brand, J. Sturis, C. F. Gotfredsen, J. Fleckner, C. Fledelius, B. F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E841 - E854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Robertson, J. Harmon, P. O. Tran, Y. Tanaka, and H. Takahashi Glucose Toxicity in {beta}-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection Diabetes, March 1, 2003; 52(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lupi, S. Del Guerra, V. Fierabracci, L. Marselli, M. Novelli, G. Patane, U. Boggi, F. Mosca, S. Piro, S. Del Prato, et al. Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin Diabetes, February 1, 2002; 51(90001): S134 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Finegood, M. D. McArthur, D. Kojwang, M. J. Thomas, B. G. Topp, T. Leonard, and R. E. Buckingham {beta}-Cell Mass Dynamics in Zucker Diabetic Fatty Rats: Rosiglitazone Prevents the Rise in Net Cell Death Diabetes, May 1, 2001; 50(5): 1021 - 1029. [Abstract] [Full Text]
|
|
|
|
|
|
M. C. Muñoz, A. Barberà, J. Domínguez, J. Fernàndez-Alvarez, R. Gomis, and J. J. Guinovart Effects of Tungstate, a New Potential Oral Antidiabetic Agent, in Zucker Diabetic Fatty Rats Diabetes, January 1, 2001; 50(1): 131 - 138. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Higa, Y.-T. Zhou, M. Ravazzola, D. Baetens, L. Orci, and R. H. Unger Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats PNAS, September 28, 1999; 96(20): 11513 - 11518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sreenan, S. Keck, T. Fuller, B. Cockburn, and C. F. Burant Effects of troglitazone on substrate storage and utilization in insulin-resistant rats Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1119 - E1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Zhou, M. Shimabukuro, M.-Y. Wang, Y. Lee, M. Higa, J. L. Milburn, C. B. Newgard, and R. H. Unger Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells PNAS, July 21, 1998; 95(15): 8898 - 8903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, F. Perusse, and L. J. Bukowiecki Mechanisms of the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker-ZDF rats Am J Physiol Regulatory Integrative Comp Physiol, May 1, 1998; 274(5): R1212 - R1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimabukuro, Y.-T. Zhou, M. Levi, and R. H. Unger Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes PNAS, March 3, 1998; 95(5): 2498 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shimabukuro, Y.-T. Zhou, Y. Lee, and R. H. Unger Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats J. Biol. Chem., February 6, 1998; 273(6): 3547 - 3550. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
